BR112021010923A2 - Análogos deuterados de acetileucina - Google Patents
Análogos deuterados de acetileucina Download PDFInfo
- Publication number
- BR112021010923A2 BR112021010923A2 BR112021010923-4A BR112021010923A BR112021010923A2 BR 112021010923 A2 BR112021010923 A2 BR 112021010923A2 BR 112021010923 A BR112021010923 A BR 112021010923A BR 112021010923 A2 BR112021010923 A2 BR 112021010923A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- solvate
- acceptable salt
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776297P | 2018-12-06 | 2018-12-06 | |
| US62/776,297 | 2018-12-06 | ||
| PCT/IB2019/060525 WO2020115715A1 (en) | 2018-12-06 | 2019-12-06 | Deuterated analogs of acetyl-leucine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021010923A2 true BR112021010923A2 (pt) | 2021-08-24 |
Family
ID=68887086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021010923-4A BR112021010923A2 (pt) | 2018-12-06 | 2019-12-06 | Análogos deuterados de acetileucina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12145899B2 (https=) |
| EP (1) | EP3886986A1 (https=) |
| JP (3) | JP7471298B2 (https=) |
| KR (2) | KR102765448B1 (https=) |
| CN (2) | CN113348018B (https=) |
| AU (1) | AU2019391434B2 (https=) |
| BR (1) | BR112021010923A2 (https=) |
| IL (2) | IL319687A (https=) |
| MA (1) | MA54289A (https=) |
| MX (2) | MX2021006559A (https=) |
| SA (1) | SA521422185B1 (https=) |
| SG (1) | SG11202106009TA (https=) |
| WO (1) | WO2020115715A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| EP3886986A1 (en) | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US20120101168A1 (en) * | 2010-10-26 | 2012-04-26 | Eliezer Bahar | Deuterium enriched rasagiline |
| ES2901752T3 (es) | 2013-02-05 | 2022-03-23 | Teva Pharmaceuticals Int Gmbh | Derivados de catecolamina enriquecidos con deuterio asimétrico de posición específica y medicamentos que comprenden dichos compuestos |
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
| DK3359146T3 (en) * | 2016-08-11 | 2019-04-08 | Intrabio Ltd | PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES |
| WO2018029658A1 (en) * | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| HUE062729T2 (hu) | 2017-03-28 | 2023-12-28 | Intrabio Ltd | Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| US12458614B2 (en) | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
| MA51836B1 (fr) | 2018-02-15 | 2025-01-31 | Intrabio Ltd | Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos |
| EP3886986A1 (en) | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| US10950670B2 (en) * | 2018-12-17 | 2021-03-16 | Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. | Display panel |
| SMT202400334T1 (it) * | 2019-03-02 | 2024-09-16 | Intrabio Ltd | (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche |
| RS67283B1 (sr) | 2019-06-28 | 2025-11-28 | Intrabio Ltd | Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja |
| WO2021144720A1 (en) * | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| US20230201150A1 (en) * | 2020-05-22 | 2023-06-29 | Intrabio Ltd. | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia |
-
2019
- 2019-12-06 EP EP19820881.1A patent/EP3886986A1/en active Pending
- 2019-12-06 AU AU2019391434A patent/AU2019391434B2/en active Active
- 2019-12-06 SG SG11202106009TA patent/SG11202106009TA/en unknown
- 2019-12-06 WO PCT/IB2019/060525 patent/WO2020115715A1/en not_active Ceased
- 2019-12-06 MX MX2021006559A patent/MX2021006559A/es unknown
- 2019-12-06 CN CN201980090399.8A patent/CN113348018B/zh active Active
- 2019-12-06 MA MA054289A patent/MA54289A/fr unknown
- 2019-12-06 CN CN202510303881.2A patent/CN120157593A/zh active Pending
- 2019-12-06 BR BR112021010923-4A patent/BR112021010923A2/pt unknown
- 2019-12-06 IL IL319687A patent/IL319687A/en unknown
- 2019-12-06 JP JP2021531964A patent/JP7471298B2/ja active Active
- 2019-12-06 KR KR1020217019782A patent/KR102765448B1/ko active Active
- 2019-12-06 IL IL283673A patent/IL283673B2/en unknown
- 2019-12-06 KR KR1020257003486A patent/KR20250022899A/ko active Pending
- 2019-12-06 US US17/311,240 patent/US12145899B2/en active Active
-
2021
- 2021-06-03 MX MX2024005670A patent/MX2024005670A/es unknown
- 2021-06-06 SA SA521422185A patent/SA521422185B1/ar unknown
-
2024
- 2024-04-09 JP JP2024062686A patent/JP2024095769A/ja not_active Withdrawn
- 2024-10-21 US US18/921,779 patent/US20250129011A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178241A patent/JP2026016521A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL283673B1 (en) | 2025-04-01 |
| JP7471298B2 (ja) | 2024-04-19 |
| KR102765448B1 (ko) | 2025-02-07 |
| EP3886986A1 (en) | 2021-10-06 |
| CN120157593A (zh) | 2025-06-17 |
| IL283673B2 (en) | 2025-08-01 |
| KR20250022899A (ko) | 2025-02-17 |
| JP2022514823A (ja) | 2022-02-16 |
| JP2026016521A (ja) | 2026-02-03 |
| AU2019391434B2 (en) | 2025-01-09 |
| WO2020115715A1 (en) | 2020-06-11 |
| JP2024095769A (ja) | 2024-07-10 |
| US12145899B2 (en) | 2024-11-19 |
| CN113348018B (zh) | 2025-04-01 |
| AU2019391434A1 (en) | 2021-07-08 |
| US20250129011A1 (en) | 2025-04-24 |
| IL319687A (en) | 2025-05-01 |
| US20220024858A1 (en) | 2022-01-27 |
| MA54289A (fr) | 2021-10-06 |
| CA3122223A1 (en) | 2020-06-11 |
| KR20210111757A (ko) | 2021-09-13 |
| SG11202106009TA (en) | 2021-07-29 |
| MX2024005670A (es) | 2024-05-30 |
| SA521422185B1 (ar) | 2024-04-24 |
| CN113348018A (zh) | 2021-09-03 |
| IL283673A (en) | 2021-07-29 |
| MX2021006559A (es) | 2021-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250129011A1 (en) | Deuterated analogs of acetyl-leucine | |
| JP5303458B2 (ja) | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 | |
| JP6320931B2 (ja) | リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ | |
| EP2086538B1 (en) | Combination therapies for treating alzheimer's disease using dimebon and donepezil | |
| EP4346788A2 (en) | Enantiomeric entactogen compositions and methods of their use | |
| JP2012523430A (ja) | 中枢神経系の変性障害の予防および／または治療方法 | |
| CN115427038A (zh) | 治疗与溶酶体贮积病相关的神经系统症状的方法 | |
| TW202337456A (zh) | Ｇｍ２神經節苷脂症之治療 | |
| JP2019524821A (ja) | リソソーム蓄積障害に関する医薬組成物及び使用 | |
| EP3989962B1 (en) | Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease | |
| BR112021015172A2 (pt) | Métodos de tratamento de sintomas e distúrbios associados a doenças de armazenamento lisossomal | |
| WO2023028091A1 (en) | Deuterated empathogens | |
| CA3122223C (en) | Deuterated analogs of acetyl-leucine | |
| RU2810793C2 (ru) | Дейтерированные аналоги ацетиллейцина | |
| US20240208895A1 (en) | Branched-chain amino acid derivatives to treat disease | |
| EP3569233A1 (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease | |
| HK40127928A (en) | Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease | |
| US12590077B2 (en) | Short-acting monoamine releasers | |
| HK40017297A (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |